drugset
drugset / Trial / NCT02787447

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

NCT02787447 ↗

Phase 2 Unknown 46 enrolled First People's Hospital of Hangzhou
NaSingle-groupOpen-labelTreatment

Summary

The investigators postulated that the exploitation of the pro-immunogenic effects of radiotherapy with thymosin might result in abscopal responses among patients with metastatic cancer. The research is designed to evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy combined with thymosin alpha 1. An exploratory biomarker analysis in blood and tumor samples is also planned.

Timeline

Start
2016-05
Primary completion
2017-12
Completion
2020-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymalfasin Peptide 1.6 mg —
Background Erlotinib Small molecule 150 mg Oral
Background Gefitinib Small molecule 250 mg Oral
Background Icotinib Small molecule 125 mg Oral

Indications

lung adenocarcinoma